Video

Kate Dawson from Biogen: Tecfidera Continues to Show Real World Success

Author(s):

It has been a few years now since Tecfidera was approved by the US Food and Drug Administration. In that time there has bee continued research which has shown positive results for patients.

It has been a few years now since Tecfidera was approved by the US Food and Drug Administration. In that time there has bee continued research which has shown positive results for patients.

Kate Dawson, MD, from Biogen discussed some of the latest data on the medication at the annual ECTRIMS conference in London. Dawson said since its approval the research has shown that the medication has followed closely with its performance during the pre-approval trials which has in turn meant beneficial results for patients. This has included several areas including safety and time to first relapse when compared to other medications on the market.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.